Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract 4055: CD40L stimulates melanoma infiltrating B cells and enhances ex vivo TIL expansion

Renata Ariza Marques Rossetti, Leticia Tordesillas, Matthew Beatty, Dongliang Du, Yian Ann Chen, Amod Sarnaik, Shari Pilon-Thomas, Daniel Abate-Daga

Cancer Res (2023) 83 (7_Supplement): 4055.

https://doi.org/10.1158/1538-7445.AM2023-4055

Published: 04 April 2023

View articletitled, Abstract 4055: CD40L stimulates melanoma infiltrating B cells and enhances ex vivo TIL expansion

Journal Articles

Abstract 2403: Targeting 4-1BB in tumors enhances anti-tumor immune responses

Amy Mackay Weber, Patrick Innamarato, Jennifer Morse, Scott Kidd, Sarah Asby, Amod Sarnaik, Shari Pilon-Thomas

Cancer Res (2019) 79 (13_Supplement): 2403.

https://doi.org/10.1158/1538-7445.AM2019-2403

Published: 01 July 2019

View articletitled, Abstract 2403: Targeting 4-1BB in tumors enhances anti-tumor immune responses

Journal Articles

Abstract CT169: A phase II, multicenter study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients with metastatic melanoma

Amod Sarnaik, Brendan Curti, Diwakar Davar, Omid Hamid, Jose Lutzky, Melissa Wilson, Harriet Kluger, Jason Chesney, Kevin Kim, Giao Phan, Sajeve Thomas, Eric Whitman, Bente Larsen, Sam Suzuki, Nancy Samberg, Igor Gorbatchevsky, Maria Fardis, John M. Kirkwood

Cancer Res (2018) 78 (13_Supplement): CT169.

https://doi.org/10.1158/1538-7445.AM2018-CT169

Published: 01 July 2018

View articletitled, Abstract CT169: A phase II, multicenter study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients with metastatic melanoma

Journal Articles

Abstract 638: Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells

Andressa L. Sodre, David M. Woods, Amod Sarnaik, Brian C. Betts, Steven Quayle, Simon Jones, Jeffrey Weber

Cancer Res (2017) 77 (13_Supplement): 638.

https://doi.org/10.1158/1538-7445.AM2017-638

Published: 01 July 2017

View articletitled, Abstract 638: Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells

Journal Articles

Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways

Tessa Knox, Maritza Lienlaf, Patricio Perez, Mibel Pabon, Calvin Lee, Fengdong Cheng, Eva Sahakian, John Powers, Susan Deng, Smalley Keiran, Alan Kozikowski, Javier Pinilla, Amod Sarnaik, Ed Seto, Jeffrey Weber, Eduardo Sotomayor, Alejandro Villagra

Cancer Res (2016) 76 (14_Supplement): 2331.

https://doi.org/10.1158/1538-7445.AM2016-2331

Published: 15 July 2016

View articletitled, Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways

Journal Articles

Abstract 2292: Reconstitution of myeloid derived suppressor cells after the induction of lymphopenia and TIL therapy

Krithika N. Kodumudi, Doris Wiener, Amy Weber, Erica Royster, Linda Kelley, Amod Sarnaik, Shari Pilon-Thomas

Cancer Res (2016) 76 (14_Supplement): 2292.

https://doi.org/10.1158/1538-7445.AM2016-2292

Published: 15 July 2016

View articletitled, Abstract 2292: Reconstitution of myeloid derived suppressor cells after the induction of lymphopenia and TIL therapy

Journal Articles

Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy

Andressa Sodre Laino, David M. Woods, Amod Sarnaik, Esteban Celis, Jeffrey Weber, Eduardo M. Sotomayor

Cancer Res (2015) 75 (15_Supplement): 1338.

https://doi.org/10.1158/1538-7445.AM2015-1338

Published: 01 August 2015

View articletitled, Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy

Journal Articles

Abstract 257: Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade

David M. Woods, Andressa L. Sodre, Amod Sarnaik, Eduardo M. Sotomayor, Jeffrey Weber

Cancer Res (2015) 75 (15_Supplement): 257.

https://doi.org/10.1158/1538-7445.AM2015-257

Published: 01 August 2015

View articletitled, Abstract 257: Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade

Journal Articles

Abstract 3136: Adoptive transfer of bone marrow T cells induces antitumor immune responses in murine models of melanoma and neuroblastoma

Krithika N. Kodumudi, Amy Weber, Ellen Moore, Amod Sarnaik, Shari Pilon-Thomas

Cancer Res (2015) 75 (15_Supplement): 3136.

https://doi.org/10.1158/1538-7445.AM2015-3136

Published: 01 August 2015

View articletitled, Abstract 3136: Adoptive transfer of bone marrow T cells induces antitumor immune responses in murine models of melanoma and neuroblastoma

Journal Articles

Abstract 4089: Histone deacetylase 6 (HDAC6) as a regulator of PD-L1 expression through STAT3 modulation in melanoma

Maritza Lienlaf, Patricio Perez-Villarroel, Calvin Lee, Fengdong Cheng, Jorge Canales, Tessa Knox, Danay Marante, Amod Sarnaik, Pedro Horna, Ed. Seto, Keiran Smalley, Jeffrey S. Weber, Eduardo M. Sotomayor, Alejandro Villagra

Cancer Res (2014) 74 (19_Supplement): 4089.

https://doi.org/10.1158/1538-7445.AM2014-4089

Published: 01 October 2014

View articletitled, Abstract 4089: Histone deacetylase 6 (HDAC6) as a regulator of PD-L1 expression through STAT3 modulation in melanoma

Journal Articles

Abstract 1248: Intralesional injection with PV-10 induces a systemic anti-tumor immune response in murine models of breast cancer and melanoma.

Shari A. Pilon-Thomas, Amy Weber, Krithika Kodumudi, Lisa Kuhn, Paul Toomey, Amod Sarnaik

Cancer Res (2013) 73 (8_Supplement): 1248.

https://doi.org/10.1158/1538-7445.AM2013-1248

Published: 15 April 2013

View articletitled, Abstract 1248: Intralesional injection with PV-10 induces a systemic anti-tumor immune response in murine models of breast cancer and melanoma.

Journal Articles

Abstract 3973: Effects of anti-PD-1 and anti-4-1BB antibody treatment on melanoma-specific T cells in a murine model of melanoma.

John L. Robinson, Krithika Kodumudi, Amy Weber, Amod Sarnaik, Shari Pilon-Thomas

Cancer Res (2013) 73 (8_Supplement): 3973.

https://doi.org/10.1158/1538-7445.AM2013-3973

Published: 15 April 2013

View articletitled, Abstract 3973: Effects of anti-PD-1 and anti-4-1BB antibody treatment on melanoma-specific T cells in a murine model of melanoma.

Journal Articles

Abstract LB-162: Blockade of PD-L1 signaling, but not depletion of regulatory T cells, delays tumor growth in a murine pancreatic tumor model

Nasreen A. Vohra, Amod Sarnaik, Amy Mackay, Tomar Ghansah, Shari Pilon-Thomas

Cancer Res (2011) 71 (8_Supplement): LB-162.

https://doi.org/10.1158/1538-7445.AM2011-LB-162

Published: 15 April 2011

View articletitled, Abstract LB-162: Blockade of PD-L1 signaling, but not depletion of regulatory T cells, delays tumor growth in a murine pancreatic tumor model

Journal Articles

Abstract #1931: Th-17 inducibility predicts freedom from relapse after CTLA-4 blockade for the treatment of advanced melanoma

Amod Sarnaik, Michael Yellin, Daohai Yu, Weiwei Zhu, Jeffrey Weber

Cancer Res (2009) 69 (9_Supplement): 1931.

Published: 01 May 2009

View articletitled, Abstract #1931: Th-17 inducibility predicts freedom from relapse after CTLA-4 blockade for the treatment of advanced melanoma

Journal Articles

β- Catenin Mutation Is a Frequent Cause of Wnt Pathway Activation in Gastric Cancer

Wilson M. Clements, Jiang Wang, Amod Sarnaik, On Ja Kim, Jack MacDonald, Cecilia Fenoglio-Preiser, Joanna Groden, Andrew M. Lowy

Cancer Res (2002) 62 (12): 3503–3506.

Published: 01 June 2002

View articletitled, β- Catenin Mutation Is a Frequent Cause of Wnt Pathway Activation in Gastric Cancer

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 4055: CD40L stimulates melanoma infiltrating B cells and enhances ex vivo TIL expansion

Abstract 2403: Targeting 4-1BB in tumors enhances anti-tumor immune responses

Abstract CT169: A phase II, multicenter study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients with metastatic melanoma

Abstract 638: Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells

Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways

Abstract 2292: Reconstitution of myeloid derived suppressor cells after the induction of lymphopenia and TIL therapy

Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy

Abstract 257: Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade

Abstract 3136: Adoptive transfer of bone marrow T cells induces antitumor immune responses in murine models of melanoma and neuroblastoma

Abstract 4089: Histone deacetylase 6 (HDAC6) as a regulator of PD-L1 expression through STAT3 modulation in melanoma

Abstract 1248: Intralesional injection with PV-10 induces a systemic anti-tumor immune response in murine models of breast cancer and melanoma.

Abstract 3973: Effects of anti-PD-1 and anti-4-1BB antibody treatment on melanoma-specific T cells in a murine model of melanoma.

Abstract LB-162: Blockade of PD-L1 signaling, but not depletion of regulatory T cells, delays tumor growth in a murine pancreatic tumor model

Abstract #1931: Th-17 inducibility predicts freedom from relapse after CTLA-4 blockade for the treatment of advanced melanoma

β- Catenin Mutation Is a Frequent Cause of Wnt Pathway Activation in Gastric Cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only